Fosravuconazole

Fosravuconazole
Clinical data
Trade names	Nailin
Other names	BMS-379224; BFE-1224; E-1224
ATC code	D01BA03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name [(2R,3R)-3-[4-(4-Cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate;
CAS Number	351227-64-0;
PubChem CID	9807507;
UNII	L4Q6O5430L;
KEGG	D10762;
CompTox Dashboard (EPA)	DTXSID70188627 ;
Chemical and physical data
Formula	C23H20F2N5O5PS
Molar mass	547.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)OCOP(=O)(O)O;

Fosravuconazole (trade name Nailin) is a triazole antifungal agent.^[1]^[2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.^[3] It is a prodrug that is converted into ravuconazole.^[1]

The Drugs for Neglected Diseases Initiative and the Japanese pharmaceutical company Eisai are studying fosravuconazole as a potential treatment for eumycetoma.^[1]^[4]^[5]

References

1 2 3 Yamaguchi H (2016). "Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93–E110. doi:10.3314/mmj.16-00006. PMID 27904057.
↑ "Fosravuconazole - Seren Pharmaceuticals". Adis Insight. Springer Nature Switzerland AG.
↑ "Oral Antifungal Agent Nailin Capsules 100 mg Approved in Japan" (Press release). Eisai. January 19, 2018.
↑ "Fosravuconazole". Drugs for Neglected Diseases Initiative.
↑ "Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma | News Release：2015 | Eisai Co., Ltd". www.eisai.com. Retrieved 2020-08-14.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.